Andros Pharmaceuticals Co (6917) Fair Value & Analysis
Healthcare · TW · Market cap 1.8B TWD
Fair value as of: Aug 13, 2026
From 1 valuation models · updated today
Share price +0.3% over the past month.
Below-average quality, and screening another 84% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (6.53 TWD). The favourable scenario is already priced in.
- Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (3.45 TWD to 6.53 TWD) leaves room in how you read the outcome.
Price vs Fair Value (8 months)
White line = price, green steps = our fair value per fiscal year. As of Aug 13, 2026.
How to read this chart
8‑month range 20.25 TWD – 43.60 TWD · fair‑value band 3.45 TWD – 6.53 TWD · the 32.05 TWD price screens above the 5.23 TWD fair value. As of Aug 13, 2026.
Analysis
Andros Pharmaceuticals Co (6917) currently trades at 32.05 TWD, while our model-based Fair Value estimate is 5.23 TWD, implying the stock looks roughly 83.7% overvalued today. The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
The balance sheet holds a net cash position of 16.8M TWD. Fundamentals as of Aug 13, 2026
Our scenario range runs from 3.45 TWD (bear case) to 6.53 TWD (bull case); at 32.05 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 60% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -47% fair-value upside, at -84%, 6917 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 6917 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 44
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies.
Full company description
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain. The company offers LALP cream for dermal analgesic applications; iMinos solution for Alopecia Androgenetica; and T4 endonuclease V. Andros Pharmaceuticals Co.,Ltd was founded in 2008 and is based in Zhubei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Andros Pharmaceuticals Co reported revenue of 5.5M TWD in FY2025 versus 13.3M TWD in FY2021, a compound −19.7%/yr. Reported net income was −53.8M TWD in FY2025.
6917 screens 84% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 600 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $525.73 | $278.78 | -47% |
| Regeneron Pharmaceuticals, Inc REGN | $797.99 | $594.40 | -26% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| WuXi Biologics (Cayman) Inc 2269 | HK$45.70 | HK$30.58 | -33% |
| Innovent Biologics, Inc 1801 | HK$95.55 | HK$19.68 | -79% |
| Genmab A/S GMAB | kr 2,037 | kr 250.07 | -88% |
| Sino Biopharmaceutical Limited 1177 | HK$4.87 | HK$3.37 | -31% |
| RemeGen Co 688331 | ¥131.87 | ¥23.19 | -82% |
| ALTEOGEN Inc 196170 | 317,500 KRW | 39,476 KRW | -88% |
Compare Andros Pharmaceuticals Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Andros Pharmaceuticals Co (6917) overvalued or undervalued?
What is the fair value of 6917?
What is the quality score of 6917?
What is the net profit margin of 6917?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Andros Pharmaceuticals Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.